🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  2. Placebo to match 10 mg, Placebo to match 5 mg

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  3. Placebo to match 100mg tablet, Lasmiditan, LASMIDITAN, Placebo to match 50mg tablet, LASMIDITAN, Placebo to match 100mg film coated tablet, Lasmiditan, Placebo to match 25mg tablet, Lasmitidan, Placebo to match 50mg film coated tablet

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  4. Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  5. Placebo to match LY

    Eli Lilly Co.

    Overweight or Obesity, OSA (Obstructive Sleep Apnea)

    phase 3 small molecule active

    1 trial

  6. Placebo to match LY, Muvalaplin

    Eli Lilly Co.

    Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  7. Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE

    Lacuna Pharma Pty Ltd

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  9. Placebo to match Paltusotine tablets 20 mg, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  10. Placebo to match abemaciclib, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  11. Placebo to match paltusotine tablets 20 mg, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  12. Placebo to match ritlecitinib 50 mg, Ritlecitinib tosilate, Ritlecitinib, Placebo to match ritlecitinib 30 mg

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  13. Placebo to remibrutinib (LOU064) 25 mg film-coated tablet, -, LOU064, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  14. Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

    TESARO Bio Netherlands B.V.

    Homologous recombination deficiency advanced ovarian cancer

    phase 3 small molecule active

    1 trial

  15. Placebo, Atoris, 40 mg, tabletki powlekane

    Bial Portela & Companhia S.A.

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  16. Placebo, Ebglyss 250 mg solution for injection in pre-filled syringe

    Almirall, S.A.

    Nummular Dermatitis

    phase 3 small molecule active

    1 trial

  17. Placebo, Etavopivat A 200 mg

    NovoThirteen

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  18. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  19. Placebo, Paltusotine 40 mg tablets, Paltusotine 40 mg tablets

    Lacuna Pharma Pty Ltd

    Carcinoid syndrome

    phase 3 small molecule active

    1 trial

  20. Placebo, Velcade and dexamethasone

    Centocor B.V.

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

  21. Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib

    Lacuna Pharma Pty Ltd

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  22. Placebo, oral solution, Maralixibat chloride

    Lacuna Pharma Pty Ltd

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

  23. Platelet Rich Plasma

    Hospital Authority, Hong Kong

    Severe Oligoasthenoteratozoospermia

    phase 3 mab completed

    1 trial

  24. Platelet Rich Plasma Injection

    United Therapeutics Europe Ltd

    Osteoarthritis of the Shoulder

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources